|
|
|
14.04.26 - 12:15
|
HENLIUS HLX05-N Phase I Clinical Trial Approved (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that its subsidiary HENLIUS (02696.HK) has received approval from the National Medical Products Administration to conduct a Phase I clinical trial of HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HENLIUS plan......
|
|
|
14.04.26 - 12:15
|
Fosun Pharma FKC289 Injection Clinical Trial Approved (AAStocks)
|
|
|
Fosun Pharma (02196.HK) announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of FKC289 injection for relapsed/refractory primary light-chain amyloidosis and relapsed/refractory membranous nephropathy. Fosun Kairui plans to carry o......
|
|
|
08.04.26 - 05:00
|
Fosun Pharma Announces Change of Chief Financial Officer (AAStocks)
|
|
|
Fosun Pharma (02196.HK) announced that the board of directors has received a written resignation letter from Chen Zhanyu. Due to adjustments in work arrangements, Chen Zhanyu has applied to resign as Chief Financial Officer, effective April 2. Following the resignation, Chen Zhanyu will continue to serve as Senior Vice President......
|
|
|
|
|
|
|
|
|
31.03.26 - 12:15
|
Fosun Pharma HLXTEHAase02 Injection Clinical Trial Approved (AAStocks)
|
|
|
Fosun Pharma (02696.HK) announced that the Phase 1 clinical trial application (IND) for its independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct the related clinical trials within mainland China (exc......
|
|
|
30.03.26 - 12:15
|
Fosun Pharma : Slulitinib Injection Receives Positive Opinion from EMA's CHMP (AAStocks)
|
|
|
Fosun Pharma (02696.HK) announced that its independently developed Slulitinib Injection (HANSIZHUANG, HETRONIFLY) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The recommendation is to approve HANSIZHUANG in combination with fluoropyrimidine and platin......
|
|
|
|
|
|
|
24.03.26 - 15:48
|
Fosun Pharma Announces 2025 Annual Results (PR Newswire)
|
|
|
Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual......
|
|
|
06.02.26 - 10:06
|
Fosun Pharma′s US$1.55 billion Eisai deal signals shift to long-term partnerships (SCMP)
|
|
|
A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development.
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations.
Under......
|
|
|
23.01.26 - 05:36
|
China′s Fosun Pharma eyes spin-off listing of vaccine unit in hot Hong Kong IPO market (SCMP)
|
|
|
The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market.
The board cleared the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical for a Hong Kong initial public offering (IPO) on Thursday, according to a late filing by Fosun Pharma, whose shares are listed in Shanghai and Hong Kong. The filing did not disclose the planned IPO......
|
|
|
|
|
|
|
07.01.26 - 01:36
|
Meow or never: China′s pudgy pets spark race for weight-loss drugs (SCMP)
|
|
|
Irina Zhou's five-year-old cat has gained about a kilogram every year for the past three years. She knows the extra weight puts her pet at risk of obesity-related diseases and could even shorten his life.
“My parents just can't bear to see the cat go hungry,” the 29-year-old Zhou said. “If the weight starts to affect his health, I might consider trying weight-loss medicines for him.”
The idea of using obesity drugs for pets drew public attention after Fosun Pharma's unit Yao Pharma signed a......
|
|
|
18.12.25 - 01:45
|
Lagging in the weight-loss market? Take Fosun′s GLP-1 pill (Bamboo Works)
|
|
|
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: By Molly Wen It's becoming a familiar story: the Chinese drugs industry has signed another licensing deal with Big Pharma to fast track a weight-loss treatment. This time.....
The post Lagging in the weight-loss market? Take Fosun's GLP-1 pill appeared first on Bamboo Works....
|
|
|
|
|
10.12.25 - 13:15
|
Pfizer Aktie: Exklusivdeal für YP05002 geschlossen - GLP-1-Projekt nimmt Fahrt auf (Aktiencheck)
|
|
|
Boston, MA (www.aktiencheck.de) - Pfizer-Aktienanalyse von Leerink Partners:
David Risinger, Analyst von Leerink Partners, stuft die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) mit "market perform" ein.
Pfizer habe am 9. Dezember 2025 bekannt gegeben, eine exklusive globale Kollaborations- und Lizenzvereinbarung mit YaoPharma, einer Tochtergesellschaft von Fosun Pharma, für YP05002 abgeschlossen zu haben - einen GLP-1RA-Small-Molecule-Kandidaten in Phase 1. [mehr]...
|
|
|
10.12.25 - 05:18
|
China′s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer (SCMP)
|
|
|
US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals.
Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
